322405-72-1

Upstream product

• 108-73-6 3,5-dihydroxyphenol 
• 13620-31-0 benzyloxyacetonitrile 
• 19810-31-2 Benzyloxyacetyl chloride 
• 82961-70-4 2-benzyloxyacetic anhydride 
• 100-51-6 benzyl alcohol 
• 5774-77-6 2-(benzyloxy)acetamide 
• 32122-09-1 ethyl benzyloxyacetate 
• 120677-47-6 1,3,5-tris(methoxymethoxy)benzene 

Downstream Products

• 950682-24-3 C₂₇H₄₂O₅Si₂ 
• 960365-81-5 2-(benzyloxy)-1-(2-hydroxy-4,6-bis(methoxymethoxy)phenyl)ethanone 
• 636559-68-7 C₆₃H₆₆O₇Si₃ 
• 1104336-75-5 C₆₃H₆₄O₆Si₃ 
• 1104334-73-7 C₇₀H₇₀O₆Si₃ 
• 636559-67-6 C₇₀H₇₂O₇Si₃ 
• 1616280-23-9 C₃₆H₂₄O₇ 
• 1616280-20-6 C₃₆H₂₆O₈ 
• 1616279-97-0 3-(benzyloxy)-5,7-dihydroxy-2-phenyl-4H-chromen-4-one 
• 322405-74-3 3-benzoyl-benzoic acid 2-benzyloxyacetyl-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-phenyl ester 
• 322405-76-5 4-azido-benzoic acid 2-benzyloxyacetyl-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-phenyl ester 
• 322405-75-4 2-(3-benzoyl-phenyl)-3-benzyloxy-5-(tert-butyl-diphenyl-silanyloxy)-7-hydroxy-chromen-4-one 
• 322405-77-6 2-(4-azido-phenyl)-3-benzyloxy-5,7-dihydroxy-chromen-4-one 

Relevant academic research and scientific papers

Method for preparing icaritin intermediate

The invention provides a method for preparing an icaritin intermediate. The method includes the steps of a, enabling phloroglucinol to react with one of a 2-benzyloxy acetylation reagent and 2-benzyloxy acetonitrile to obtain 2-benzyloxy-1-(2,4,6-trihydroxyphenyl)ethanone; b. subjecting a reaction product obtained from the step a and p-methoxybenzoyl halide to Baker-Venkataraman reaction so as toobtain 3-(benzyloxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-4H-benzopyran-4-one; c. subjecting the reaction product obtained in the step b to hydrogenation so as to obtain the icaritin intermediate, namely 3,5,7-trihydroxy-2-(4-methoxyphenyl)-4H-benzopyran-4-one.

Gram-scale synthesis of anti-pancreatic flavonoids (±)-8-[1- (4′-hydroxy-3′-methoxyphenyl)prop-2-en-1-yl]-chrysin and -galangin

Gram-scale total synthesis of (±)-8-[1-(4′-hydroxy-3′- methoxyphenyl)prop-2-en-1-yl]-galangin (1) and -chrysin (2) has been accomplished in eight steps from commercially available phloroglucinol and three steps from commercially available chrysin, respect

Total synthesis of acetylcholinesterase inhibitor macakurzin C

A concise total synthesis of macakurzin C has been accomplished in nine steps (21% overall yield) from commercially available phloroglucinol, featuring a sequential aromatic Claisen rearrangement-cyclization.

BENZOPYRONE ESTROGEN RECEPTOR REGULATOR

The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.

BENZOPYRONE ESTROGEN RECEPTOR REGULATOR

The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.

Enantioselective synthesis of the complex rocaglate (-)-silvestrol

The total synthesis of the natural product (-)-silvestrol (1) has been accomplished and features enantioselective [3+2] photocycloaddition of a substituted 3-hydroxyflavone and methyl cinnamate promoted by a chiral Bronsted acid. Initial biological studies indicate a 5-10-fold greater activity of silvestrol as an inhibitor of protein synthesis in HeLa cells than its 1″″ diastereomer.

Synthesis of pelargonidin 3-O-6″-O-acetyl-β-d-glucopyranoside, an acylated anthocyanin, via the corresponding kaempferol glucoside

The first total synthesis of pelargonidin 3-O-6″-O-acetyl-β-d-glucopyranoside, an acylated anthocyanin of magenta-colored Verbena flowers, was successfully carried out. The key intermediate, protected kaemferol 3-O-glucoside, was constructed by the Baker-

RSK INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.

Synthesis of flavonol derivatives as probes of biological processes

Two synthetic derivatives of the flavonol kaempferol were prepared in order to probe the biological mechanism of action of this natural product. Efficient synthetic routes to both a benzophenone-containing derivative and an amine-containing derivative are reported herein. (C) 2000 Elsevier Science Ltd.